Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to
evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of
platinum-resistant recurrent epithelial ovarian cancer，primary fallopian tube cancer and
primary peritoneal carcinoma.